Fulcrum Therapeutics reduces workforce from 80 to 51, expects $10M annual savings

Fulcrum Therapeutics, Inc.

Workforce reduction of 29 employees (36%) to focus on pociredir, DBA, and early discovery; suspends losmapimod.
One-time severance costs of approximately $2 million expected in Q3 2024.
Annual operating expense savings of about $10 million anticipated starting Q1 2025.
Majority of costs incurred by September 30, 2024; implementation substantially complete by Q3 end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.